Project Grant HT94252410122

The National Institute on Aging (NIA) awarded The University of Pennsylvania a $6.72 million Project Grant on September 15, 2025, under the Aging Research program (CFDA 93.866) to develop short RNA therapeutics targeting TDP-43 proteinopathy. The project, which extends through August 31, 2029, addresses the absence of effective treatments for neurodegenerative disorders—including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), limbic-predominant...

The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...

The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

Federal Project Grant Award Summary Yale University received a $446,670 Project Grant awarded May 6, 2026, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research and development of bi-functional helical peptides designed to inhibit transactive response DNA-binding protein 43 (TDP-43) aggregation, a pathological hallmark of amylotrophic lateral...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support a two-year research investigation through May 31, 2027. The project, titled "Investigating the Role of TDP-43 Citrullination in ALS Pathogenesis," focuses on understanding how...

Federal Project Grant Award Summary Aquinnah Pharmaceuticals, Inc. received a $1,499,212 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 15, 2025, with completion targeted for May 31, 2027. The award supports the development of a novel oral, brain-penetrant therapeutic candidate designed to treat amyotrophic lateral sclerosis...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...

The U.S. Defense Health Agency awarded a $1,979,313 Project Grant to Sachi Bioworks, Inc., a small disadvantaged business in Erie, Colorado, to develop a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). This award is part of the agency's Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. Sachi Bioworks specializes...